Clinical Trials
2 trialsNCT04220203 2025-06-26
Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer
Seagen Inc.
Approved for marketing
NCT03424473 2020-02-25
Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer
Seagen Inc.
No longer available